An Introduction to Liquid Biopsy
In the field of oncology, the ability to understand the specific genetic makeup of a patient’s cancer is essential for delivering personalized treatment. For decades, the only way to obtain this information was through a traditional tissue biopsy, a procedure that involves surgically removing a piece of the tumor for analysis. While tissue biopsies remain a gold standard for initial diagnosis, a revolutionary technology known as a liquid biopsy has emerged as a powerful and complementary tool.
A liquid biopsy is a simple blood test that can provide a wealth of information about a cancer without the need for an invasive surgical procedure. It represents a major step forward in precision oncology, allowing doctors to detect cancer-specific mutations, monitor treatment response, and track the evolution of a cancer over time. In advanced cancer centers across Turkey, liquid biopsy is increasingly being integrated into the standard of care for many patients with advanced cancer.
What is a Liquid Biopsy?
A liquid biopsy is a laboratory test performed on a sample of blood to look for tiny pieces of cancer cells or cancer DNA that have been shed from a tumor and are circulating in the bloodstream. Even very small tumors can release these materials into the blood. By capturing and analyzing this material, doctors can gain valuable insights into the genetic characteristics of a patient’s cancer.
The two main components that a liquid biopsy can detect are:
- Circulating Tumor DNA (ctDNA): As tumor cells die, they break apart and release fragments of their DNA into the bloodstream. This ctDNA contains the same genetic mutations as the tumor itself. A liquid biopsy uses highly sensitive technology to find and sequence this ctDNA. This is a key part of genetic testing.
- Circulating Tumor Cells (CTCs): In some cases, whole cancer cells can break away from the main tumor and enter the bloodstream. A liquid biopsy can also be designed to isolate and analyze these rare cells.
Essentially, a liquid biopsy provides a real-time “snapshot” of the cancer’s genetic profile, all from a simple blood draw.
The Primary Uses of Liquid Biopsy in Cancer Care
The information gained from a liquid biopsy has several important applications in the management of cancer, particularly for patients with advanced or metastatic disease.
1. Guiding Personalized Treatment
This is currently the most important and well-established use of liquid biopsy. Many modern cancer treatments are targeted therapies—drugs that work by attacking cancer cells with a specific genetic mutation. A liquid biopsy can analyze the ctDNA to identify these mutations.
- Identifying Therapeutic Targets: If the test finds a specific mutation (like an EGFR mutation in lung cancer or a PIK3CA mutation in breast cancer), it can tell the oncologist that the patient is a candidate for a targeted therapy drug designed to attack that specific mutation.
- Detecting Resistance Mutations: Cancers can be clever and may develop new mutations over time that make them resistant to a previously effective targeted therapy. A liquid biopsy can detect these new resistance mutations, explaining why a treatment may have stopped working and guiding the oncologist to switch to a different therapy.
2. Monitoring Treatment Response
The amount of ctDNA in the bloodstream often correlates with the amount of cancer in the body. By measuring the levels of ctDNA over time, a liquid biopsy can help monitor how well a treatment is working. A significant decrease in the level of ctDNA can be an early indicator that the treatment is effective, sometimes even before changes are visible on a CT or PET scan. Conversely, a rising level of ctDNA may signal that the cancer is growing or becoming resistant.
3. Detecting Minimal Residual Disease (MRD) and Recurrence
After a curative surgery or treatment, there may be a tiny number of cancer cells remaining in the body that are too small to be detected by conventional scans. This is called minimal residual disease (MRD). A highly sensitive liquid biopsy can sometimes detect the ctDNA shed from these few remaining cells. The presence of ctDNA after treatment may indicate a very high risk of the cancer returning (recurring). This information could one day be used to help doctors decide which patients need additional (adjuvant) therapy.
Liquid Biopsy vs. Traditional Tissue Biopsy
It is important to understand that a liquid biopsy does not replace the traditional tissue biopsy in all situations. They are often seen as complementary tools.
- Initial Diagnosis: A traditional tissue biopsy is still the gold standard for the initial diagnosis of cancer. A pathologist needs to look at the tumor cells under a microscope to confirm the cancer type and grade.
- When Tissue is Unavailable: A liquid biopsy is extremely valuable when getting a tissue sample is difficult or risky. For example, if a lung cancer patient has a tumor deep in their chest, or if they are too frail for an invasive procedure, a liquid biopsy can provide the necessary genetic information from a simple blood test.
- Tracking Cancer Evolution: A tissue biopsy only provides information from one part of the tumor at a single point in time. Because tumors can be heterogeneous (different parts can have different mutations) and can evolve over time, a liquid biopsy offers an advantage. It can capture a more complete picture of the cancer’s genetic landscape from all tumor sites in the body and can be repeated easily over time to track changes.
The Patient Experience: What to Expect
For the patient, the process of having a liquid biopsy is remarkably simple and non-invasive.
- The Procedure: The procedure is the same as a routine blood test. A nurse or phlebotomist will draw one or two vials of blood from a vein in your arm.
- No Special Preparation: Unlike many other diagnostic tests, there is no special preparation required. You do not need to fast or alter your daily routine before the blood draw.
- Analysis: The blood sample is sent to a specialized molecular pathology laboratory. In the lab, the blood is processed to separate the plasma (the liquid portion of the blood) from the blood cells. Highly advanced technology, typically Next-Generation Sequencing (NGS), is then used to find and analyze the tiny fragments of ctDNA present in the plasma.
The Role of the Medical Oncologist
The liquid biopsy test is ordered and interpreted by your medical oncologist. They will determine if and when a liquid biopsy is the appropriate test for your specific situation. After the test is completed, the laboratory provides a detailed report listing any cancer-related mutations that were found. Your oncologist will then have a consultation with you to explain what the results mean in the context of your cancer and how they will be used to guide your treatment plan.
Frequently Asked Questions
1. Is a liquid biopsy a replacement for a traditional tissue biopsy?
Not always. A traditional tissue biopsy is still essential for the initial diagnosis of most cancers. However, a liquid biopsy is an incredibly valuable tool, especially when a tissue biopsy is difficult or risky to perform, or when doctors need to monitor for changes in the cancer’s genetic makeup over time without repeated invasive procedures. They are often seen as complementary tests.
2. Is the liquid biopsy test painful?
No. The procedure itself is as painless as a standard blood test. It involves a simple blood draw from a vein in your arm.
3. What is the main purpose of using a liquid biopsy in cancer care today?
Currently, the most important and widespread use of liquid biopsy is to guide treatment for patients with advanced or metastatic cancer. By analyzing the circulating tumor DNA (ctDNA) in the blood, the test can identify specific genetic mutations in the cancer, which helps the oncologist choose a personalized targeted therapy drug that is most likely to be effective.
4. Can a liquid biopsy be used for any type of cancer?
The utility of liquid biopsy can vary by cancer type and stage. It is most commonly used for advanced solid tumors, such as non-small cell lung cancer, breast cancer, colorectal cancer, and prostate cancer, where identifying specific mutations is crucial for guiding targeted therapy. Its use is expanding rapidly as the technology improves.
5. How long does it take to get the results from a liquid biopsy?
After the blood sample is drawn, it is sent to a specialized laboratory for complex genetic analysis. The turnaround time for the results is typically between one and three weeks. Your oncologist will schedule a follow-up appointment to discuss the report with you once it is available.
6. Can a liquid biopsy be used for early cancer screening in healthy people?
This is a major area of ongoing research and great excitement. While some “multi-cancer early detection” blood tests are in development and showing promise in clinical trials, the use of liquid biopsy for routine cancer screening in the general, healthy population is not yet a standard medical practice. Its primary established role is in managing patients who have already been diagnosed with cancer.
7. Is a liquid biopsy test something I can order myself?
No. A liquid biopsy is a complex medical test that must be ordered by a qualified physician, such as a medical oncologist. More importantly, the results must be interpreted by an expert in the context of your specific medical situation to be meaningful and to accurately guide your treatment.
